Skip to main content
. 2011 May;32(5):882–889. doi: 10.3174/ajnr.A2385

Fig 3.

Fig 3.

Kaplan-Meier analysis of up-front bevacizumab-treated (A and C) and control (B and D) patients. The upper row represents progression-free survival, whereas the lower row is overall survival. For all graphs, the y-axis represents the percentage surviving.